Bullish
Zenas BioPharma (ZBIO) is progressing with its Phase 3 clinical trial for orelabrutinib, a BTK inhibitor, targeting primary progressive multiple scler...
Tomas Kiselak has resigned from the board of Zenas BioPharma (ZBIO) following the expiration of his term. He did not seek re-election at the company's...
Neutral
Zenas BioPharma (ZBIO) reported a Q1 net loss of $1.46 per share, which is slightly better than FactSet's estimated loss of $1.47 per share. The compa...
Bullish
Zenas BioPharma has announced significant progress in its clinical trials and financial standing. The company plans to submit marketing applications f...